We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
Wall Street analysts forecast that Biogen Inc. (BIIB - Free Report) will report quarterly earnings of $3.94 per share in its upcoming release, pointing to a year-over-year decline of 25.4%. It is anticipated that revenues will amount to $2.32 billion, exhibiting a decrease of 5.8% compared to the year-ago quarter.
Over the last 30 days, there has been a downward revision of 2.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Biogen metrics that Wall Street analysts commonly model and monitor.
The consensus estimate for 'Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total' stands at $372.66 million. The estimate points to a change of -19.4% from the year-ago quarter.
The average prediction of analysts places 'Revenue- Product- Rare Disease- SPINRAZA- Total' at $396.92 million. The estimate suggests a change of -7.5% year over year.
Analysts expect 'Revenue- Product- Rare Disease- SKYCLARYS- Total' to come in at $128.37 million. The estimate indicates a year-over-year change of +28.4%.
Analysts' assessment points toward 'Revenue- Product, net' reaching $1.72 billion. The estimate suggests a change of -9.5% year over year.
Analysts forecast 'Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Rest of world' to reach $171.91 million. The estimate suggests a change of -19.5% year over year.
Based on the collective assessment of analysts, 'Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- United States' should arrive at $203.91 million. The estimate indicates a year-over-year change of -18%.
It is projected by analysts that the 'Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- United States' will reach $32.02 million. The estimate suggests a change of -27.4% year over year.
Analysts predict that the 'Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- Rest of world' will reach $143.72 million. The estimate suggests a change of -30.9% year over year.
The collective assessment of analysts points to an estimated 'Revenue- Product- Rare Disease- SPINRAZA- Rest of World' of $244.01 million. The estimate points to a change of -10.2% from the year-ago quarter.
The consensus among analysts is that 'Revenue- Product- Rare Disease- SPINRAZA- United States' will reach $156.29 million. The estimate indicates a year-over-year change of -0.6%.
The combined assessment of analysts suggests that 'Revenue- Product- Multiple Sclerosis (MS)- Interferon- United States' will likely reach $129.57 million. The estimate indicates a change of -10.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- Product- Multiple Sclerosis (MS)- Interferon- Rest of world' should come in at $94.29 million. The estimate suggests a change of -10.6% year over year.
Over the past month, shares of Biogen have returned -1.7% versus the Zacks S&P 500 composite's +3.4% change. Currently, BIIB carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Wall Street analysts forecast that Biogen Inc. (BIIB - Free Report) will report quarterly earnings of $3.94 per share in its upcoming release, pointing to a year-over-year decline of 25.4%. It is anticipated that revenues will amount to $2.32 billion, exhibiting a decrease of 5.8% compared to the year-ago quarter.
Over the last 30 days, there has been a downward revision of 2.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Biogen metrics that Wall Street analysts commonly model and monitor.
The consensus estimate for 'Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total' stands at $372.66 million. The estimate points to a change of -19.4% from the year-ago quarter.
The average prediction of analysts places 'Revenue- Product- Rare Disease- SPINRAZA- Total' at $396.92 million. The estimate suggests a change of -7.5% year over year.
Analysts expect 'Revenue- Product- Rare Disease- SKYCLARYS- Total' to come in at $128.37 million. The estimate indicates a year-over-year change of +28.4%.
Analysts' assessment points toward 'Revenue- Product, net' reaching $1.72 billion. The estimate suggests a change of -9.5% year over year.
Analysts forecast 'Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Rest of world' to reach $171.91 million. The estimate suggests a change of -19.5% year over year.
Based on the collective assessment of analysts, 'Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- United States' should arrive at $203.91 million. The estimate indicates a year-over-year change of -18%.
It is projected by analysts that the 'Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- United States' will reach $32.02 million. The estimate suggests a change of -27.4% year over year.
Analysts predict that the 'Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- Rest of world' will reach $143.72 million. The estimate suggests a change of -30.9% year over year.
The collective assessment of analysts points to an estimated 'Revenue- Product- Rare Disease- SPINRAZA- Rest of World' of $244.01 million. The estimate points to a change of -10.2% from the year-ago quarter.
The consensus among analysts is that 'Revenue- Product- Rare Disease- SPINRAZA- United States' will reach $156.29 million. The estimate indicates a year-over-year change of -0.6%.
The combined assessment of analysts suggests that 'Revenue- Product- Multiple Sclerosis (MS)- Interferon- United States' will likely reach $129.57 million. The estimate indicates a change of -10.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- Product- Multiple Sclerosis (MS)- Interferon- Rest of world' should come in at $94.29 million. The estimate suggests a change of -10.6% year over year.
View all Key Company Metrics for Biogen here>>>Over the past month, shares of Biogen have returned -1.7% versus the Zacks S&P 500 composite's +3.4% change. Currently, BIIB carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .